Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Priya Bahri

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
Drug Safety|October 30, 2020
Proposals for Engaging Patients and Healthcare Professionals in Risk Minimisation from an Analysis of Stakeholder Input to the EU Valproate Assessment Using the Novel Analysing Stakeholder Safety Engagement Tool (ASSET)Priya Bahri, Daniel R Morales, Adrien Inoubli, et al.
Drug Safety|September 2, 2011
Communication in drug safety: a report from an interactive debate held at the 10th annual meeting of the international society of pharmacovigilance (ISoP), 2010Priya Bahri, Peter G M Mol, Hélène Théophile, et al.
Drug Safety|July 29, 2021
Authors' Reply to Braillon and Martin's Comment on "Proposals for Engaging Patients and Healthcare Professionals in Risk Minimisation from an Analysis of Stakeholder Input to the EU Valproate Assessment using the Novel Analysing Stakeholder Safety Engagement Tool (ASSET)"Priya Bahri, Daniel R Morales, Adrien Inoubli, et al.
Drug Safety|March 13, 2025
Using Mixed Methods to Evaluate Risk Minimisation Programs in Europe and the USA: An Innovative BlueprintMeredith Y Smith, Rachel Davis, Priya Bahri, et al.
International Journal of Epidemiology|June 28, 2021
The role of epidemiologists in communicating SARS-CoV-2 evidence: a call for adopting standardsMeredith Y Smith, Priya Bahri, James A Gaudino, et al.
Drug Safety|May 25, 2023
The ISoP PatEG-SIG for Promoting Patient Engagement in Pharmacovigilance: A Change of Paradigm is NeededManal M Younus, Mayada Alkhakany, Priya Bahri, et al.
Expert Opinion on Drug Safety|October 8, 2022
How do safety warnings on medicines affect prescribing?Barbara Mintzes, Ellen Reynolds, Priya Bahri, et al.
Drug Safety|December 9, 2017
The RIMES Statement: A Checklist to Assess the Quality of Studies Evaluating Risk Minimization Programs for Medicinal ProductsMeredith Y Smith, Andrea Russell, Priya Bahri, et al.
Clinical Pharmacology and Therapeutics|August 9, 2020
Postmarket Safety Communication for Protection of Public Health: A Comparison of Regulatory Policy in Australia, Canada, the European Union, and the United StatesAlice L Bhasale, Ameet Sarpatwari, Marie L De Bruin, et al.
Drug Safety|September 26, 2019
Authors' Reply to Ravi Jandhyala's Comment on "Patient Registries: An Underused Resource for Medicines Evaluation: Operational Proposals for Increasing the Use of Patient Registries in Regulatory Assessments"Patricia McGettigan, Carla Alonso Olmo, Kelly Plueschke, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
Drug Safety|October 30, 2020
Proposals for Engaging Patients and Healthcare Professionals in Risk Minimisation from an Analysis of Stakeholder Input to the EU Valproate Assessment Using the Novel Analysing Stakeholder Safety Engagement Tool (ASSET)Priya Bahri, Daniel R Morales, Adrien Inoubli, et al.
Drug Safety|September 2, 2011
Communication in drug safety: a report from an interactive debate held at the 10th annual meeting of the international society of pharmacovigilance (ISoP), 2010Priya Bahri, Peter G M Mol, Hélène Théophile, et al.
Drug Safety|July 29, 2021
Authors' Reply to Braillon and Martin's Comment on "Proposals for Engaging Patients and Healthcare Professionals in Risk Minimisation from an Analysis of Stakeholder Input to the EU Valproate Assessment using the Novel Analysing Stakeholder Safety Engagement Tool (ASSET)"Priya Bahri, Daniel R Morales, Adrien Inoubli, et al.
Drug Safety|March 13, 2025
Using Mixed Methods to Evaluate Risk Minimisation Programs in Europe and the USA: An Innovative BlueprintMeredith Y Smith, Rachel Davis, Priya Bahri, et al.
International Journal of Epidemiology|June 28, 2021
The role of epidemiologists in communicating SARS-CoV-2 evidence: a call for adopting standardsMeredith Y Smith, Priya Bahri, James A Gaudino, et al.
Drug Safety|May 25, 2023
The ISoP PatEG-SIG for Promoting Patient Engagement in Pharmacovigilance: A Change of Paradigm is NeededManal M Younus, Mayada Alkhakany, Priya Bahri, et al.
Expert Opinion on Drug Safety|October 8, 2022
How do safety warnings on medicines affect prescribing?Barbara Mintzes, Ellen Reynolds, Priya Bahri, et al.
Drug Safety|December 9, 2017
The RIMES Statement: A Checklist to Assess the Quality of Studies Evaluating Risk Minimization Programs for Medicinal ProductsMeredith Y Smith, Andrea Russell, Priya Bahri, et al.
Clinical Pharmacology and Therapeutics|August 9, 2020
Postmarket Safety Communication for Protection of Public Health: A Comparison of Regulatory Policy in Australia, Canada, the European Union, and the United StatesAlice L Bhasale, Ameet Sarpatwari, Marie L De Bruin, et al.
Drug Safety|September 26, 2019
Authors' Reply to Ravi Jandhyala's Comment on "Patient Registries: An Underused Resource for Medicines Evaluation: Operational Proposals for Increasing the Use of Patient Registries in Regulatory Assessments"Patricia McGettigan, Carla Alonso Olmo, Kelly Plueschke, et al.
Pageof 4